Summary
The pharmacokinetic parameters of deacetyl metipranolol were determined after i.v. infusion of increasing doses (6–25 mg) in 17 normal volunteers. In a second cross-over trial, deacetyl metipranolol 10 and 20 mg were infused in a further 10 subjects, and in a third trial another 20 volunteers received metipranolol 40 mg orally. Metipranolol is very rapidly and completely deacetylated in man, so all pharmacokinetic data refer to deacetyl metipranolol, which was assayed by gas chromatography-mass spectrometry. The pharmacokinetic analysis was performed using a recently developed model, using a volume of distribution which is variable with time. The following data were obtained after oral administration: (mean values); lag-time 7.3 min; tmax 50 min, invasion half-life 6.3 min; elimination half-life 3 h; urinary excretion of unchanged drug approximately 4% of the dose. The experiments with infusion of increasing doses, as well as the cross-over study with 10 and 20 mg i.v., showed dose-linearity of the kinetics. The respective mean half-lives of elimination were 2.6, 2.9 and 2.8 h. The mean total, renal and extra-renal clearances amounted to 1237 ml/min, 149 ml/min and 1068 ml/min, respectively. The distribution coefficient was 3.5 l/kg, and protein binding amounted to 70% within the range of therapeutic concentrations. Absolute bioavailability was found to be approximately 50% by several different evaluation procedures. Thus, the pharmacokinetic profile of metipranolol shares features of both the lipophilic and the hydrophilic groups of β-blocking agents.
Similar content being viewed by others
References
Abshagen U (1980) Internal report Boehringer Mannheim
Betzien G (1979) Dokumentation einer Bioverfügbarkeitsstudie. In: Schnieders B, Rietbrock N (eds) Bioverfügbarkeit von Arzneimitteln. Gustav Fischer Stuttgart
Endele R, Senn M, Abshagen U (1981) Determination of deacetyl-metipranolol in body fluids by GC-MS J. Chromatogr (in press)
Harlik J, Janků I, Trěka V (1972) Desacetylace trimepranolu v plasme ruzuych zvirecich druku in vitro Cs. Fyziol 21:275
Johnsson G, Regårdh CG (1976) Clinical Pharmacokinetics of β-adrenoceptor blocking drugs Clin. Pharmacokinet 1:233–263
Mayer O, Čepelák V, Vitouš J, Potměšil J (1980) β-blocking drug metipranolol: plasma levels and pharmacodynamic action in man. Int J Clin Pharmacol Ther Toxicol 18: 113–120
Melander A, Danielson K, Schersten B, Wahlin E (1977) Enhancement of the bioavailability of propranolol and metoprolol by food. Clin Pharmacol Ther 22: 108–112
Pentikäinen PJ, Neuvonen PJ, Penttilä A (1978) Assessment of β-blocking activity of trimepranol in man Int J Clin Pharmacol 16: 279–284
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Abshagen, U., Betzien, G., Kaufmann, B. et al. Pharmacokinetics of metipranolol in normal man. Eur J Clin Pharmacol 21, 293–301 (1982). https://doi.org/10.1007/BF00637616
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00637616